Harold Burstein graduated from Harvard College before earning his MD at Harvard Medical School. He also received a PhD in cellular immunology and a master's degree in the history of science from Harvard. Dr. Burstain trained in internal medicine at Massachusetts General Hospital before his oncology fellowship at DFCI. Dr Burstein is board certified in medical oncology and internal medicine. In 1999, he joined the staff of DFCI and Brigham and Women's Hospital, where he is a clinician and clinical investigator in the Breast Oncology Center.
Ian Krop received his MD and PhD degrees from the Johns Hopkins School of Medicine in 1996 and completed a residency in internal medicine at Johns Hopkins Hospital. After completing a medical oncology fellowship at the Dana-Farber Cancer Institute, Dr. Krop joined the faculty of the Women’s Cancer Program at Dana-Farber and Harvard Medical School where he is now an Assistant Professor of Medicine. His clinical and laboratory research focuses on developing novel molecularly targeted therapies for breast cancer treatment and on understanding and overcoming mechanisms of resistance to HER2 directed therapies.
Jennifer Ligibel received her B.S. from Duke University and her M.D. from the Washington University School of Medicine. Following her residency in internal medicine at Massachusetts General Hospital, she completed a medical oncology fellowship at Dana-Farber Cancer Institute. In 2001, Dr. Ligibel joined the staff at Dana-Farber, where she works in the Women’s Cancer Program, specializing in breast cancer.
Dr. Ligibel’s research is focused on exercise and diet in cancer patients. Her work has been funded by the Lance Armstrong Foundation and the American Society of Clinical Oncology. She has recently completed two studies looking at the impact of exercise on breast cancer patients during and after treatment. Her work has demonstrated that exercise can help lower levels of hormones potentially linked to breast cancer development and recurrence. Her ongoing work looks at the potential benefits of exercise in women with advanced breast cancer.
Nancy Lin is an Instructor in Medicine at Harvard Medical School. Dr. Lin received her MD from Harvard Medical School and completed her residency in Internal Medicine at Brigham & Women’s Hospital. She went on to complete fellowships in hematology and medical oncology at Dana-Farber/Partners Cancer Care. She is a medical oncologist at Dana-Farber Cancer Institute where she divides her time between caring for patients with breast cancer and conducting clinical research.
Erica Mayer received her medical degree from Harvard Medical School in 2000. Dr. Mayer subsequently completed her residency in Internal Medicine at Brigham and Women's Hospital, and her fellowship in Medical Oncology at Dana-Farber Cancer Institute. She obtained a Master's in Public Health from the Harvard School of Public Health in 2005. Dr. Mayer joined the staff of Dana-Farber and Brigham and Women's Hospital in 2006, where she is a medical oncologist and clinical investigator in the Breast Oncology Center.In addition she is an instructor in medicine at Harvard Medical School. Her research focuses on novel therapies in the treament of breast cancer.
Ann Partridge received her MD from Cornell University Medical College in 1995. Dr. Partridge completed her residency in internal medicine at the Hospital of the University of Pennsylvania and went on to complete fellowships in medical oncology and hematology at Dana Farber Cancer Institute. Later she received a Masters of Public Health from Harvard School of Public Health. Dr. Partridge is a medical oncologist focusing on the care of women with breast cancer, and she has a particular interest in breast cancer care and treatment of young women.
Daniel Silver received his medical school training at the University of California, San Francisco, and was an oncology fellow at the Dana -Farber/Partners oncology training program. Dr. Silver is board-certified in oncology. In addition to his medical training, he has a Ph.D. in biology from MIT, where he trained at the Whitehead Institute for Biomedical Research with Drs. David Baltimore and Richard Mulligan. Dr. Silver did postdoctoral training at the Dana-Farber Cancer Institute with Dr. David Livingston. His research interests include the functions of the BRCA genes, and the properties of the sporadic Basal-like triple-negative breast cancers.
Eric P. Winer is Chief, Division of Women’s Cancers and the Thompson Senior Investigator in Breast Cancer Research at Dana-Farber Cancer Institute. He is also an Professor of Medicine at Harvard Medical School. Dr. Winer received his undergraduate and medical degrees from Yale University. After completing internal medicine and medical oncology training at Yale and Duke, he was on the faculty at Duke Medical Center for eight years before moving to Dana-Farber Cancer Institute in 1997. Dr. Winer is widely published, having authored over 200 articles, clinical communications, reviews, book chapters, and editorials. He serves on the editorial board for several peer-reviewed publications, including the Journal of Clinical Oncology and Breast Cancer Research and Treatment. Dr. Winer is co-chair of Cancer and Leukemia Group B (CALGB) Breast Committee. Dr. Winer is the current chair of the American Society of Clinical Oncology's Cancer Communications Committee. Dr. Winer is also the Chief Scientific Advisor and Chair of the Scientific Advisory Board for Susan G. Komen for the Cure.